MANKIND · Mankind Pharma Limited · Financials
Volume · Nov 13
34.82K
Avg daily vol (3M)
53.08K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
142.78B
+17%
FY2026
Net Income
19.13B
-3.7%
FY2026
Operating Cash Flow
31.21B
+29.3%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| INR | 153.79B | 142.78B | 122.07B | 103.35B | 87.49B |
| INR | 9.07B | 8.86B | 6.21B | 3.98B | 3.26B |
| INR | 5.14B | 6.39B | 4.29B | 335.32M | 444.69M |
| INR | 6.03B | 3.95B | 5.1B | 4.58B | 3.62B |
| INR | 22.49B | 19.13B | 19.86B | 19.13B | 12.82B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2026: 412.7M in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.